Deep Track Biotechnology Master Fund, Ltd.
10% Owner
- 2025
- Aug 10, 2026
- 6
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Deep Track Biotechnology Master Fund, Ltd. files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- GOLDMAN SACHS GROUP INC - $27.32M in ATTO purchases and sales in the last 12 months
- Colin Walsh - $27.32M in ATTO purchases and sales in the last 12 months
- Redmile Group, LLC - $10.20M in ATTO purchases and sales in the last 12 months
- Frazier Life Sciences XI, L.P. - $10.00M in ATTO purchases and sales in the last 12 months
- venBio Global Strategic Fund IV, L.P. - $6.50M in ATTO purchases and sales in the last 12 months
- Sanofi - $5.10M in ATTO purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
What is Deep Track Biotechnology Master Fund, Ltd.?
Deep Track Biotechnology Master Fund, Ltd. is an investment firm, tracked as 10% Owner of Attovia Therapeutics, Inc. (ATTO). InsiderAlpha holds 6 primary Form 4 filings for it, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Deep Track Biotechnology Master Fund, Ltd. submitted recently?
2 primary Form 4 filings in the last 90 days, covering 2 companies.
Has Deep Track Biotechnology Master Fund, Ltd. been buying or selling stock?
Recorded transactions: 5 open-market purchases ($60.00M) and 2 open-market sales ($22.35M) across all tracked filings.
